W·Consumer Cyclical
Wayfair Earnings -12% Plunge After Profit Miss Shock
Are Wayfair earnings signaling a temporary stumble or the start of a deeper reset in the home-furnishings e-commerce trade? Maik…
Stocks
W·Consumer Cyclical
AMD·Technology·AI
AMD AI Demand +4.5% Rally: Is a New Data Center Boom Starting?
Is surging AMD AI Demand signaling just another semiconductor swing trade, or the start of a multi-year data center upgrade…
HOOD·Financial Services·Crypto-related Stocks
Robinhood Earnings Q1: Revenue Miss but HOOD Jumps 2.6%
Are weaker Robinhood Earnings just a crypto hangover—or the start of a deeper shift in how this fintech makes its…
CMG·Consumer Cyclical
Chipotle Earnings +2.9% Surge as Margins Get Squeezed
Can Chipotle Earnings keep the stock rallying even as rising costs and thinner margins test the burrito giant’s comeback story?…
MA·Financial Services·Fintech
Mastercard Earnings -5%: Cross-Border Warning Rattles Investors
Are Mastercard’s latest earnings strong enough to offset fresh worries about a sudden slowdown in lucrative cross-border spending? Maik Kemper…
ABBV·Healthcare·Dividend Aristocrats
AbbVie Earnings +4.5% Surge After Bullish Upgrade Shock
Are AbbVie Earnings and a surprise Bank of America upgrade signaling a new phase in the pharma giant’s post-Humira transition?…
LLY·Healthcare·Pharma
Eli Lilly Earnings Soar 156% as GLP‑1 Boom Lifts Outlook
Are Eli Lilly earnings finally proving that the GLP‑1 obesity boom can justify today’s sky‑high valuation? Maik Kemper Editor in…
MARA·Financial Services·Crypto-related Stocks
MARA Acquisition +12.3% Rally: AI Power Bet Shocks Crypto Market
Can the MARA Acquisition of Long Ridge really turn a volatile Bitcoin miner into a stable, AI‑powered energy and compute…
GEHC·Healthcare
GE HealthCare Earnings Shock After Q1 Miss and Outlook Cut
Are GE HealthCare Earnings flashing a temporary warning sign or the start of a deeper rerating for this medtech heavyweight?…
LLY·Healthcare·Pharma
Eli Lilly Earnings Surge 56% as Stock Soars 8.3%
Can Eli Lilly’s explosive GLP-1 demand and raised outlook really justify one of the richest valuations in global pharma? Maik…